Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05649748 · ClinicalTrials.gov registry record · Phase 2
An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)
A Phase 2 study of Pulmonary Arterial Hypertension, sponsored by Insmed Incorporated.
- Active
- Registry status
- Phase 2
- Development phase
- 91
- Enrollment target
- 20
- Study locations
NCT05649748: Active Phase 2 study of Pulmonary Arterial Hypertension, sponsored by Insmed Incorporated.
NCT05649748 is a Phase 2 study of Pulmonary Arterial Hypertension that is active but no longer recruiting, run by Insmed Incorporated. The registered enrollment target is 91 participants, below the 461-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05649748, a Phase 2 study of Pulmonary Arterial Hypertension, is active but no longer recruiting, sponsored by Insmed Incorporated.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 91 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary purpose of the study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PAH from studies INS1009-201 (NCT04791514), INS1009-202 (NCT05147805) and other lead-in studies of TPIP in participants with PAH.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Treprostinil Palmitil
Study Locations (20)
Other
- ARG004 - Córdoba
- ARG001 - Córdoba
- AUT001 - Vienna
- BEL003 - Brussels
Florida
- USA005 - Jacksonville
- USA011 - Tampa
Illinois
- USA006 - Chicago
- USA001 - Chicago
New York
- USA102 - New York
Texas
- USA016 - Dallas
Buenos Aires
- ARG009 - Quilmes
Santa Fe Province
- ARG006 - Rosario
Tucumán Province
- ARG007 - San Miguel de Tucumán
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2023-03-07 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
What the registry record for NCT05649748 still lists
NCT05649748 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 91 participants, a relatively small participant target, below the 461-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Pulmonary Arterial Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05649748 names 20 study sites across 15 states, led by Other, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT05649748 about?
NCT05649748 is a clinical study titled "An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)". The primary purpose of the study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PAH from studies INS1009-201 (NCT04791514), INS1009-202 (NCT05147805) and other lead-in studies of TPIP in participants with PAH.
What is the current status of trial NCT05649748?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 91 participants. The study started on 2023-03-07. Estimated completion is 2026-12-31.
What conditions does trial NCT05649748 study?
This clinical trial studies the following conditions: Pulmonary Arterial Hypertension.
What interventions are being tested in trial NCT05649748?
The interventions under investigation include: Placebo (DRUG), Treprostinil Palmitil (DRUG).
Who is sponsoring clinical trial NCT05649748?
This trial is sponsored by Insmed Incorporated, which has 31 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05649748 being conducted?
This trial has 20 study locations across Florida, Illinois, New York, Texas, Buenos Aires. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Arterial Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05649748's enrollment target sits among peer trials
91 21st of 63 higher than 43 of 63 other Pulmonary Arterial Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Arterial Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)
RECRUITING · Phase 2
-
Pulmonary Hypertension SOLAR
RECRUITING · Phase 2
-
Xenon MRI Pulm Hypertension
RECRUITING · Phase 2
-
Repurposing Valsartan May Protect Against Pulmonary Hypertension
RECRUITING · Phase 2
-
Spironolactone for Pulmonary Arterial Hypertension
RECRUITING · Phase 2
-
129 Xenon Imaging in Patients Treated With Sotatercept
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02671448 · 91 participants · NA
Pilot Trial of Homebound Stem Cell Transplantation
- NCT04835857 · 91 participants
Comparison of Cuff-Less Wrist Wearable Blood Pressure Device to Cuff Based Blood Pressure Measuring Devices
- NCT05184842 · 91 participants · Phase 2
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
- NCT05685173 · 91 participants · Phase 1
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI